Mutations in CHEK2 Associated with Prostate Cancer Risk
β Scribed by Xiangyang Dong; Liang Wang; Ken Taniguchi; Xianshu Wang; Julie M. Cunningham; Shannon K. McDonnell; Chiping Qian; Angela F. Marks; Susan L. Slager; Brett J. Peterson; David I. Smith; John C. Cheville; Michael L. Blute; Steve J. Jacobsen; Daniel J. Schaid; Donald J. Tindall; Stephen N. Thibodeau; Wanguo Liu
- Book ID
- 117854119
- Publisher
- American Society of Human Genetics
- Year
- 2003
- Tongue
- English
- Weight
- 641 KB
- Volume
- 72
- Category
- Article
- ISSN
- 0002-9297
- DOI
- 10.1086/346094
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract The 1100delC mutation of the cell cycle checkpoint kinase 2 (__CHEK2__) gene confers an increased risk for breast cancer, but the clinical impact of other __CHEK2__ gene variants remains unclear. We determined the frequency of two functionally relevant __CHEK2__ gene mutations, I157T an
## Abstract Germline mutations in __CHEK2__ have been associated with a range of cancer types but little is known about disease risks conveyed by __CHEK2__ mutations outside of the context of breast and prostate cancer. To investigate whether __CHEK2__ mutations confer an increased risk of bladder